Dear John,

Join us for a free live taping of A Health Podyssey on October 22 where Jennifer Kao will discuss her upcoming paper exploring the impact of risk evaluation and mitigation strategies on generic approvals of US pharmaceutical products.

Health Affairs Scholar September 2025

Volume 3, Issue 9 of Health Affairs Scholar highlights Medicare Advantage incentives and zero-premium plans, the Inflation Reduction Act’s impact on pharmaceutical investment, barriers to accessing the Earned Income Tax Credit, strategies to support behavioral health for older adults, and more.

Be sure to check out the full issue on the Scholar website.

Editor’s Choice

“It's confusing as hell”: a qualitative study of barriers accessing poverty alleviation benefits through the US Earned Income Tax Credit 

Wendi Gosliner et al.

Mental health crises and help-seeking among US adults in 2024-2025 

Andrew Anderson et al.

Commentary

How time is accounted for when modeling pharmaceutical impacts: investment vs assessment perspectives

Melanie D Whittington et al.

Research Letter

Diagnosed health conditions and health care use among Medicaid expansion enrollees, 2019 and 2022

William L Schpero et al.

Health Affairs Branded Post:

Roberto Servi

Sponsored by Lilly

Medicaid’s Role in Rising Buprenorphine Use w/ Stephen Crystal

Health Affairs' Rob Lott interviews Stephen Crystal of Rutgers University about his recent paper exploring how states with substantial increases in buprenorphine uptake as an opioid use disorder treatment response grew alongside increased Medicaid prescribing from 2018–24.

Reforming Medicare Quality Measurement

Joel White et al.

Leading Health Policy Scholars: Medicaid Work Requirements Won’t Increase Employment

Dhruv Khullar et al.